Fingolimod
Fingolimod is a once-daily oral medicine for relapsing forms of multiple sclerosis (MS) in adults and children 10 and older, available as capsules and as an orally disintegrating tablet.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 23 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Fingolimod (Gilenya) is a once-daily oral medicine for relapsing forms of multiple sclerosis in people 10 and older, the first oral MS treatment, around since about 2010 and available as a generic; it holds lymphocytes (a type of white blood cell) in the lymph nodes so fewer may reach the brain. Most people tolerate it well, noticing mainly headache, diarrhea, cough, or flu and sinus infections. Watch for a slow heartbeat after the first dose (hence at least 6 hours of observation) and, longer term, infections such as shingles or PML, a rare brain infection. Don't stop it or skip checkups without your prescriber's okay, since MS can rebound severely.
Clinical pearls
- Make sure every prescriber knows you take it, since beta blockers, diltiazem, verapamil and digoxin can deepen the first-dose heart slowing.
- Expect regular eye exams, because fingolimod can cause macular edema (swelling at the back of the eye), and report any vision change.
- Have your chickenpox immunity checked before starting, and avoid live vaccines during treatment and for 2 months after stopping.
- Use effective contraception throughout treatment and for 2 months afterward, because fingolimod can harm a developing baby.
Patient information guide A plain-language walkthrough of Fingolimod, written from its FDA label.
What Fingolimod is used for
▾
Fingolimod treats relapsing forms of multiple sclerosis (MS).
- Clinically isolated syndrome
- Relapsing-remitting disease
- Active secondary progressive disease
- For patients 10 years and older: Fingolimod capsules, Gilenya capsules and Tascenso ODT (orally disintegrating tablet)
How Fingolimod works
▾
Fingolimod is converted in the body to fingolimod-phosphate, which binds to sphingosine 1-phosphate receptors. This traps lymphocytes in the lymph nodes, so fewer circulate in the blood.
The exact way this helps MS isn't known. It may involve fewer immune cells moving into the central nervous system (brain and spinal cord).
Fingolimod dosage
▾
Fingolimod is taken by mouth once daily, with or without food. Your dose depends on your age and, for children, weight, so follow your prescriber and label.
- Gilenya and fingolimod capsules are swallowed.
- Tascenso ODT is placed on the tongue to dissolve, with or without water.
- Your first dose is monitored for at least 6 hours. The same monitoring is repeated if you restart after missing more than 14 days, and may be repeated when the dose increases.
Dosing details from the FDA-approved label
From the Fingolimod prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Adults and pediatric patients (10 years of age and older) weighing more than 40 kg
- 0.5 mg orally once daily, with or without food
- Fingolimod doses higher than 0.5 mg are associated with a greater incidence of adverse reactions without additional benefit; first-dose monitoring required
- Pediatric patients (10 years of age and older) weighing less than or equal to 40 kg
- 0.25 mg orally once daily, with or without food
- First-dose monitoring required, also recommended when the dose is increased in pediatric patients
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION • Assessments are required prior to initiating fingolimod capsules. ( 2.1 ) • Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2 , 2.3 ) • Recommended dosage for pediatric patients (10 years of age and above) weighing less than or equal to 40 kg: 0.25 mg orally once daily, with or without food. ( 2.2 , 2.3 ) • First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): o Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) o Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) o Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) o Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. ( 2.4 , 7.1 ) 2.1 Assessment Prior to Initiating Fingolimod Capsules Cardiac Evaluation Obtain a cardiac evaluation in patients with certain preexisting conditions [see Warnings and Precautions (5.1)] . Prior to starting treatment, determine whether patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction [ see Dosage and Administration (2.4) , Drug Interactions (7.5) ] . Complete Blood Count (CBC) Review results of a recent CBC [ see Warnings and Precautions (5.2) , Drug Interactions (7.6) ] . Serum Transaminases (ALT and AST) and Total Bilirubin Levels Prior to starting treatment with fingolimod capsules (i.e., within 6 months), obtain serum transaminases [alanine transaminase (ALT) and aspartate transferase (AST)] and total bilirubin levels [see Warnings and Precautions (5.5) ] . Ophthalmic Assessment Obtain a baseline evaluation of the fundus, including the macula, near the start of the treatment with fingolimod capsules [see Warnings and Precautions (5.4) ].
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Fingolimod side effects
▾
The most common side effects in studies were:
Common side effects
- Headache
- Liver enzyme elevation (shown on blood tests)
- Diarrhea
- Cough
- Influenza (flu)
- Sinusitis (sinus infection)
- Back pain
- Abdominal pain
- Pain in arms or legs
When to get medical help
- Call your doctor if you have signs of infection, such as fever, or symptoms that suggest shingles, herpes or meningitis. Serious and even fatal infections have occurred.
- Get help for dizziness, fainting, chest pain, palpitations or unusual fatigue, especially in the first day after a dose. These can signal a slow heartbeat or heart block.
- Report new or worsening weakness, vision or thinking changes, or other new neurological symptoms right away. These can be signs of PML, a rare brain infection.
- Tell your doctor about any change in vision. Fingolimod can cause macular edema (swelling in the back of the eye).
- Report signs of liver problems, such as unexplained nausea, yellowing of skin or eyes, or dark urine.
- Report rash, hives or swelling after starting treatment. These may be a hypersensitivity reaction.
- Report a sudden severe worsening of MS after stopping, or a severe relapse during treatment.
- Seizures have been reported in children; get help right away if one occurs.
Fingolimod warnings and precautions
▾
- Slow heart rate and heart block can happen after the first dose, so monitoring is required.
- Infections can be serious or fatal, including shingles, herpes, cryptococcal infection and PML. Monitoring continues for 2 months after stopping.
- Macular edema: eye exams are done at the start, 3 to 4 months in, and when vision changes. Diabetes and uveitis raise the risk.
- Liver injury: liver tests are done before and during treatment.
- Pregnancy: may cause fetal harm.
- After stopping: a severe increase in disability can occur.
- Other risks: high blood pressure, skin cancers, breathing effects, PRES, and hypersensitivity reactions.
Fingolimod interactions
▾
Several drugs and vaccines need extra care with fingolimod.
- Beta blockers, digoxin, diltiazem, verapamil: may add to a slow heartbeat.
- QT-prolonging drugs (citalopram, haloperidol, methadone, erythromycin and others): raise the risk of heart rhythm problems.
- Ketoconazole: raises fingolimod levels.
- Corticosteroids and other immune-suppressing drugs: add to immune suppression.
- Live vaccines: avoid during treatment and for 2 months after.
Interactions listed in the FDA-approved label
From the Fingolimod prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Systemic ketoconazole: Blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold, and the risk of adverse reactions is increased. Monitor closely during concomitant use.
- Vaccines (live attenuated): Fingolimod reduces the immune response to vaccination; vaccination may be less effective during and for up to 2 months after discontinuation, and live vaccines carry a risk of infection. Avoid live attenuated vaccines during and for 2 months after treatment.
- QT-prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin): Fingolimod initiation decreases heart rate and may prolong the QT interval; QT-prolonging drugs have been associated with torsades de pointes in patients with bradycardia. Monitor overnight with continuous ECG in a medical facility.
- Antineoplastic, immunosuppressive, or immune-modulating therapies (including corticosteroids): Expected to increase the risk of immunosuppression through additive immune system effects. Consider the risk of additive immune effects when coadministered; when switching from drugs with prolonged immune effects such as natalizumab, teriflunomide or mitoxantrone, consider their duration and mode of action.
- Drugs that slow heart rate or AV conduction (e.g., beta blockers, digoxin, diltiazem, verapamil): Concomitant use during initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician about switching to drugs that do not slow heart rate or AV conduction; patients who cannot switch should have overnight continuous ECG monitoring after the first dose.
- Laboratory tests (peripheral blood lymphocyte counts): Fingolimod reduces blood lymphocyte counts via redistribution in secondary lymphoid organs, so peripheral lymphocyte counts cannot be used to evaluate lymphocyte subset status. A recent CBC should be available before initiating treatment.
Read the label’s full interactions text
7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. ( 7.2 , 12.3 ) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping Fingolimod treatment. ( 5.2 , 7.3 ) 7.1 QT Prolonging Drugs Fingolimod Capsules has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of Fingolimod Capsules treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 )] . 7.2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use Fingolimod Capsules and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is increased. 7.3 Vaccines Fingolimod Capsules reduces the immune response to vaccination. Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with Fingolimod Capsules [see Clinical Pharmacology ( 12.2 )] . Avoid the use of live attenuated vaccines during and for 2 months after treatment with Fingolimod Capsules because of the risk of infection. It is recommended that pediatric patients, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines prior to initiating Fingolimod Capsules therapy.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Fingolimod
▾
- Recent heart attack, unstable angina, stroke, TIA or serious heart failure (past 6 months): do not use.
- Certain heart block, sick sinus syndrome, QTc of 500 msec or more, or need for Class Ia or III anti-arrhythmic drugs: do not use.
- Allergy to fingolimod: do not use.
- Active infection: treatment should wait until it resolves.
- Pregnancy: use effective contraception during treatment and for 2 months after; stop 2 months before planned conception, and discuss the risk of MS worsening.
- Breastfeeding: discuss with your doctor.
- Adults 65 and older: use caution.
- Severe liver impairment: closer monitoring.
Fingolimod overdose
▾
Too much fingolimod can cause a slow heartbeat and AV block, usually starting within an hour. The label says patients should be observed overnight with continuous ECG monitoring in a medical facility, with regular blood pressure checks. Dialysis and plasma exchange do not remove fingolimod.
What Fingolimod does in the body
▾
Fingolimod causes a temporary drop in heart rate and AV conduction at the start of treatment. Heart rate returns to baseline within about a month. It lowers blood lymphocytes to roughly 30% of baseline, and counts typically recover within 1 to 2 months after stopping. It also weakens vaccine responses.
How your body processes Fingolimod
▾
Fingolimod is well absorbed (about 93%) and food does not change absorption. It reaches peak levels in 12 to 16 hours. Steady state takes 1 to 2 months. The half-life is 6 to 9 days, so effects fade over about 2 months after stopping. It is mostly broken down in the body, and about 81% leaves in urine as inactive metabolites.
How to store Fingolimod
▾
stored at 20ºC to 25ºC (68ºF to 77ºF); excursions permitted to 15ºC to 30ºC (59ºF to 86ºF) . Protect from moisture.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Fingolimod
106 supplements and herbal products have documented interactions with Fingolimod in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 4
- Moderate · 92
- Minor · 10
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Fingolimod: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Fingolimod — the kind of thing our pharmacy team would talk through with you at the counter.
What is fingolimod for?
▾
How do I take it?
▾
Why do I have to be watched after the first dose?
▾
What side effects should I expect, and which need a call?
▾
Can I get vaccines?
▾
What if I might become pregnant?
▾
Is Fingolimod available over the counter?
▾
When was Fingolimod first available?
▾
Who makes Fingolimod?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Fingolimod on HelloPharmacist
Fingolimod forms and strengths (how it comes)
Fingolimod is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Capsule
How this form is used
- Gilenya is used for relapsing forms of multiple sclerosis in patients 10 years and older.
- Fingolimod capsules are used for relapsing forms of multiple sclerosis in patients 10 years and older.
- Gilenya is taken by mouth once daily, with or without food.
- Gilenya requires first-dose heart monitoring, and assessments such as blood counts, liver tests, an eye exam and a skin exam are done around the start of treatment.
Orally disintegrating tablet
How this form is used
- Tascenso ODT is used for relapsing forms of multiple sclerosis in patients 10 years and older.
- Tascenso ODT is taken by mouth once daily, with or without food.
- Tascenso ODT can be taken with or without water; place the tablet directly on the tongue and let it dissolve before swallowing.
- Tascenso ODT requires first-dose heart monitoring and assessments before starting.
Fingolimod on the U.S. market: products, makers and brands
How Fingolimod appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
23 companies list 25 Fingolimod product records with the FDA, mostly as capsule, orally disintegrating tablet; the earliest marketing or approval year on record is 2010. Brand names on the directory include Gilenya, Tascenso, Tascenso Odt; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (18) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Fingolimod is used (Medicaid data)
A general measure of how commonly Fingolimod is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Fingolimod is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Fingolimod prescribed? Of the 1,601 medications we measure, Fingolimod ranks #990 by Medicaid prescriptions — more than 38% of them.
Utilization by Fingolimod product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
fingolimod 0.5 MG Oral Capsule Most dispensed
Summed across the 7 of 59 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1012895
fingolimod 0.5 MG Disintegrating Oral Tablet
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2626383
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Fingolimod, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 8 of 60 listed Fingolimod NDCs with Medicaid activity.
Compare Fingolimod products
A representative set of FDA-listed product records for Fingolimod — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 0.5 mg | Oral | Accord Healthcare Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Alembic Pharmaceuticals Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Alembic Pharmaceuticals Limited | ANDA | View NDC → |
| 0.5 mg | Oral | Apotex Corp. | ANDA | View NDC → |
| 0.5 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Aurobindo Pharma Limited | ANDA | View NDC → |
| 0.5 mg | Oral | AvKARE | ANDA | View NDC → |
| 0.5 mg | Oral | Biocon Pharma Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | CivicaScript LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| 0.5 mg | Oral | Glenmark Pharmaceuticals Inc., USA | ANDA | View NDC → |
| 0.5 mg | Oral | Novadoz Pharmaceuticals LLC | ANDA | View NDC → |
| 0.25 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 0.5 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 0.5 mg | Oral | Quallent Pharmaceuticals Health LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Solco Healthcare US, LLC | ANDA | View NDC → |
| 0.5 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Teva Pharmaceuticals, Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | XLCare Pharmaceuticals Inc. | ANDA | View NDC → |
| 0.5 mg | Oral | Zydus Lifesciences Limited | ANDA | View NDC → |
| 0.5 mg | Oral | Zydus Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 💊Orally disintegrating tablet | ||||
| 0.25 mg | Oral | Cycle Pharmaceuticals Ltd | NDA | View NDC → |
| 0.5 mg | Oral | Cycle Pharmaceuticals Ltd | NDA | View NDC → |
Showing 25 of 25 products — FDA National Drug Code Directory. See every product, package size and price: browse all 25 Fingolimod NDCs →
Fingolimod side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Fingolimod — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Fingolimod in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Fingolimod FDA approval history
How Fingolimod went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Fingolimod recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list one Fingolimod recall since July 2021. It is still ongoing. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Fingolimod Capsules, 0.5 mg, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-476-30. Lots: Lot 22122841, Exp August 2025 FDA record D-0925-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1012892 2 dose forms · 4 strengths
-
Dose form (SCDF) Disintegrating Oral Tablet RxCUI 2610294No current FDA listing -
Dose form (SCDF) Oral Capsule RxCUI 1012894In current FDA listings
Look up RxCUI 1012892 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Fingolimod supply and shortage status
Whether Fingolimod is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Fingolimod costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Mar 11, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Capsule · Oral | 0.5 mg | $414.71 per capsule | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Fingolimod brand names
Fingolimod is sold under 3 brand names in the FDA directory — Gilenya, Tascenso, Tascenso Odt. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Fingolimod: manufacturers and labelers
23 companies list Fingolimod products with the FDA. By number of product records, the largest are Cycle Pharmaceuticals Ltd, Novartis Pharmaceuticals Corporation, Accord Healthcare Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Fingolimod drug class (RxNorm)
Fingolimod belongs to the Sphingosine 1-phosphate Receptor Modulator class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Fingolimod page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Biocon Pharma Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →